Fate Therapeutics (FATE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
The annual meeting is scheduled for June 12, 2026, with four main proposals: election of three Class I directors, ratification of Ernst & Young LLP as auditor, a non-binding say-on-pay vote, and approval of an amendment to the 2022 Stock Option and Incentive Plan to increase reserved shares by 7,000,000.
Voting rights are one vote per share, with 116,281,693 shares outstanding as of April 15, 2026; a majority constitutes a quorum.
The board recommends voting FOR all proposals.
Voting matters and shareholder proposals
Proposal 1: Elect three Class I directors (Robert S. Epstein, Karin Jooss, Laura J. Hamill) for a term ending 2029.
Proposal 2: Ratify Ernst & Young LLP as independent auditor for 2026.
Proposal 3: Non-binding advisory vote on executive compensation (say-on-pay).
Proposal 4: Approve amendment to increase shares reserved under the 2022 Stock Option and Incentive Plan by 7,000,000.
Shareholder proposals for the 2027 meeting must be submitted by December 25, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The board is divided into three classes, with staggered three-year terms; currently eight members, increasing to nine.
All directors except the CEO are independent per Nasdaq and SEC rules.
Board committees: Audit, Compensation, Nominating and Corporate Governance, and Science & Technology (advisory).
Board diversity includes three female directors and three from underrepresented communities.
Director nominations emphasize integrity, experience, and diversity.
Latest events from Fate Therapeutics
- FT819 advances off-the-shelf CAR T into lupus nephritis and broader autoimmune care.FATE
Jefferies Global Healthcare Conference - $100 million Leerink ATM adds financing flexibility but carries material dilution risk.FATE
Registration filing - RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis.FATE
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATE
Q2 2026 - Early lupus trial data with flexible CAR T protocols expected by year-end, focusing on B-cell reset.FATE
Jefferies 2024 Global Healthcare Conference - FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATE
Corporate presentation - Net loss narrowed on lower expenses, with strong cash and key CAR T-cell advances, but risks remain.FATE
Q1 2026 - Key votes include director elections, auditor ratification, and incentive plan amendment.FATE
Proxy filing